|
|
| G
|
Ache
|
acetylcholinesterase
|
affects activity multiple interactions
|
EXP
|
mancozeb affects the activity of ACHE protein [carbendazim co-treated with mancozeb] results in increased activity of ACHE protein
|
CTD |
PMID:10641187 PMID:33217513 |
|
NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410
|
|
| G
|
Actg1
|
actin, gamma 1
|
increases expression
|
ISO
|
mancozeb results in increased expression of ACTG1 protein
|
CTD |
PMID:21375462 |
|
NCBI chr10:106,118,106...106,120,951
Ensembl chr10:106,118,108...106,120,951
|
|
| G
|
Actmap
|
actin maturation protease
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of ACTMAP mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr 1:91,618,012...91,627,490
Ensembl chr 1:91,617,859...91,627,489
|
|
| G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
ISO
|
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of AKT1 protein; [alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of AKT1 protein
|
CTD |
PMID:19883720 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
| G
|
Alb
|
albumin
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of ALB protein
|
CTD |
PMID:21375462 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
|
|
| G
|
Aldh2
|
aldehyde dehydrogenase 2 family member
|
decreases activity multiple interactions
|
EXP ISO
|
mancozeb results in decreased activity of ALDH2 protein [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of ALDH2 mRNA; [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of and results in decreased activity of ALDH2 protein
|
CTD |
PMID:17010440 PMID:34830855 |
|
NCBI chr12:40,610,244...40,643,220
Ensembl chr12:40,610,224...40,643,219
|
|
| G
|
Aldh5a1
|
aldehyde dehydrogenase 5 family, member A1
|
decreases activity
|
EXP
|
mancozeb results in decreased activity of ALDH5A1 protein
|
CTD |
PMID:17010440 |
|
NCBI chr17:40,560,373...40,586,711
Ensembl chr17:40,558,347...40,586,714
|
|
| G
|
Angptl1
|
angiopoietin-like 1
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of ANGPTL1 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr13:71,463,913...71,531,810
Ensembl chr13:71,511,727...71,531,818
|
|
| G
|
Anxa2
|
annexin A2
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of ANXA2 protein
|
CTD |
PMID:21375462 |
|
NCBI chr 8:78,986,252...79,022,638
Ensembl chr 8:78,986,242...79,022,631
|
|
| G
|
Ar
|
androgen receptor
|
multiple interactions decreases expression decreases activity
|
ISO
|
mancozeb inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; mancozeb inhibits the reaction [Metribolone binds to and results in increased activity of AR protein] mancozeb results in decreased expression of AR mRNA mancozeb results in decreased activity of AR protein
|
CTD |
PMID:23871939 PMID:33396126 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467
|
|
| G
|
Atp1a2
|
ATPase Na+/K+ transporting subunit alpha 2
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of ATP1A2 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr13:87,261,964...87,286,911
Ensembl chr13:87,261,968...87,286,911
|
|
| G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression multiple interactions
|
ISO
|
mancozeb results in increased expression of BAX mRNA mancozeb results in increased expression of BAX protein [Sulfur co-treated with mancozeb co-treated with metrafenone] results in decreased expression of BAX mRNA; [Sulfur co-treated with mancozeb] results in decreased expression of BAX mRNA; lupeol inhibits the reaction [mancozeb results in increased expression of BAX mRNA]
|
CTD |
PMID:27235710 PMID:35564597 PMID:35617905 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
| G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases expression multiple interactions
|
ISO EXP
|
mancozeb results in decreased expression of BCL2 mRNA mancozeb results in decreased expression of BCL2 protein [Sulfur co-treated with mancozeb co-treated with metrafenone] results in decreased expression of BCL2 mRNA; [Sulfur co-treated with mancozeb] results in decreased expression of BCL2 mRNA; lupeol inhibits the reaction [mancozeb results in decreased expression of BCL2 mRNA] alpha-Tocopherol inhibits the reaction [mancozeb results in decreased expression of BCL2 protein]
|
CTD |
PMID:16005924 PMID:27235710 PMID:35564597 PMID:35617905 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
| G
|
Ca3
|
carbonic anhydrase 3
|
increases expression
|
ISO
|
mancozeb results in increased expression of CAR3 protein
|
CTD |
PMID:21375462 |
|
NCBI chr 2:88,491,666...88,501,299
Ensembl chr 2:88,491,670...88,500,524
|
|
| G
|
Casp3
|
caspase 3
|
increases activity increases expression multiple interactions increases cleavage
|
ISO
|
mancozeb results in increased activity of CASP3 protein mancozeb results in increased expression of CASP3 protein Acetylcysteine inhibits the reaction [mancozeb results in increased cleavage of CASP3 protein]
|
CTD |
PMID:22824503 PMID:30037311 PMID:35617905 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
| G
|
Casp7
|
caspase 7
|
increases activity
|
ISO
|
mancozeb results in increased activity of CASP7 protein
|
CTD |
PMID:22824503 |
|
NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512
|
|
| G
|
Casp8
|
caspase 8
|
increases activity
|
ISO
|
mancozeb results in increased activity of CASP8 protein
|
CTD |
PMID:22824503 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
| G
|
Casp9
|
caspase 9
|
increases activity increases expression
|
ISO
|
mancozeb results in increased activity of CASP9 protein mancozeb results in increased expression of CASP9 protein
|
CTD |
PMID:22824503 PMID:35617905 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
| G
|
Cat
|
catalase
|
multiple interactions decreases activity
|
ISO EXP
|
Acetylcysteine inhibits the reaction [mancozeb results in decreased activity of CAT protein]; lupeol inhibits the reaction [mancozeb results in decreased activity of CAT protein]; Quercetin inhibits the reaction [mancozeb results in decreased activity of CAT protein] Colforsin inhibits the reaction [mancozeb results in decreased activity of CAT protein]
|
CTD |
PMID:23024109 PMID:27235710 PMID:29283200 PMID:30037311 PMID:35617905 PMID:36007320 More...
|
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
| G
|
Ccdc106
|
coiled-coil domain containing 106
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of CCDC106 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr 1:77,808,723...77,812,816
Ensembl chr 1:77,808,723...77,852,105
|
|
| G
|
Ccnd1
|
cyclin D1
|
multiple interactions increases expression
|
ISO
|
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of CCND1 protein mancozeb results in increased expression of CCND1 protein
|
CTD |
PMID:19883720 PMID:21375462 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
| G
|
Cdc25c
|
cell division cycle 25C
|
increases phosphorylation
|
ISO
|
mancozeb results in increased phosphorylation of CDC25C protein
|
CTD |
PMID:21375462 |
|
NCBI chr18:26,608,483...26,630,292
Ensembl chr18:26,609,959...26,630,292
|
|
| G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
multiple interactions increases expression
|
ISO
|
lupeol inhibits the reaction [mancozeb results in increased expression of CDKN1A mRNA]
|
CTD |
PMID:27235710 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
| G
|
Cfap126
|
cilia and flagella associated protein 126
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of CFAP126 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr13:86,059,142...86,075,034
Ensembl chr13:86,059,142...86,075,034
|
|
| G
|
Cldn16
|
claudin 16
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of CLDN16 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr11:87,795,106...87,814,396
Ensembl chr11:87,795,106...87,814,396
|
|
| G
|
Ctf1
|
cardiotrophin 1
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of CTF1 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr 1:191,758,512...191,771,259
Ensembl chr 1:191,757,477...191,776,395
|
|
| G
|
Cycs
|
cytochrome c, somatic
|
increases expression
|
ISO
|
mancozeb results in increased expression of CYCS protein
|
CTD |
PMID:27016407 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816 Ensembl chr18:80,982,668...80,984,816
|
|
| G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
decreases activity decreases expression
|
EXP ISO
|
mancozeb results in decreased activity of CYP1A1 protein mancozeb results in decreased expression of CYP1A1 protein
|
CTD |
PMID:1946188 PMID:31096615 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
| G
|
Cyp2b3
|
cytochrome P450, family 2, subfamily b, polypeptide 3
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of CYP2B6 protein
|
CTD |
PMID:31096615 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
| G
|
Cyp2e1
|
cytochrome P450, family 2, subfamily e, polypeptide 1
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of CYP2E1 mRNA
|
CTD |
PMID:31096615 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495
|
|
| G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of CYP3A4 mRNA; mancozeb results in decreased expression of CYP3A4 protein
|
CTD |
PMID:31096615 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
| G
|
Ddit4
|
DNA-damage-inducible transcript 4
|
increases expression
|
EXP
|
mancozeb results in increased expression of DDIT4 protein
|
CTD |
PMID:24764117 |
|
NCBI chr20:28,434,938...28,437,037
Ensembl chr20:28,434,944...28,437,037
|
|
| G
|
Dnmt1
|
DNA methyltransferase 1
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of DNMT1 protein
|
CTD |
PMID:36007320 |
|
NCBI chr 8:27,716,797...27,763,405
Ensembl chr 8:27,716,797...27,763,119
|
|
| G
|
Dnmt3a
|
DNA methyltransferase 3 alpha
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of DNMT3A protein
|
CTD |
PMID:36007320 |
|
NCBI chr 6:32,507,316...32,621,678
Ensembl chr 6:32,512,070...32,614,970
|
|
| G
|
Dusp1
|
dual specificity phosphatase 1
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of DUSP1 mRNA
|
CTD |
PMID:36007320 |
|
NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644
|
|
| G
|
Efcab12
|
EF-hand calcium binding domain 12
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of EFCAB12 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr 4:150,541,983...150,563,973
Ensembl chr 4:150,541,982...150,563,286
|
|
| G
|
Efna1
|
ephrin A1
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of EFNA1 mRNA
|
CTD |
PMID:36007320 |
|
NCBI chr 2:176,979,434...176,988,675
Ensembl chr 2:176,979,434...176,988,726
|
|
| G
|
Efna3
|
ephrin A3
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of EFNA3 mRNA
|
CTD |
PMID:36007320 |
|
NCBI chr 2:177,026,928...177,035,838
Ensembl chr 2:177,026,933...177,044,843
|
|
| G
|
Elk1
|
ETS transcription factor ELK1
|
increases phosphorylation
|
ISO
|
mancozeb results in increased phosphorylation of ELK1 protein
|
CTD |
PMID:21375462 |
|
NCBI chr X:3,692,367...3,709,252
Ensembl chr X:3,693,293...3,709,249
|
|
| G
|
Esr1
|
estrogen receptor 1
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of ESR1 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354
|
|
| G
|
Esr2
|
estrogen receptor 2
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of ESR2 mRNA; mancozeb results in decreased expression of ESR2 protein
|
CTD |
PMID:33396126 |
|
NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709
|
|
| G
|
F3
|
coagulation factor III, tissue factor
|
increases expression
|
ISO
|
mancozeb results in increased expression of F3 protein
|
CTD |
PMID:25569083 |
|
NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369
|
|
| G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of FOS mRNA
|
CTD |
PMID:36007320 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
| G
|
Gadd45a
|
growth arrest and DNA-damage-inducible, alpha
|
multiple interactions decreases expression increases expression
|
ISO
|
lupeol inhibits the reaction [mancozeb results in increased expression of GADD45A mRNA] mancozeb results in decreased expression of GADD45A mRNA
|
CTD |
PMID:27235710 PMID:36007320 |
|
NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807
|
|
| G
|
Glyatl3
|
glycine-N-acyltransferase-like 3
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of GLYATL3 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr 9:27,474,057...27,492,281
Ensembl chr 9:27,474,057...27,492,281
|
|
| G
|
Got1
|
glutamic-oxaloacetic transaminase 1
|
affects activity
|
EXP
|
mancozeb affects the activity of GOT1 protein
|
CTD |
PMID:10641187 |
|
NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871
|
|
| G
|
Gpt
|
glutamic--pyruvic transaminase
|
affects activity multiple interactions
|
EXP
|
mancozeb affects the activity of GPT protein [2-cyano-N-((ethylamino)carbonyl)-2-(methoxyimino)acetamide co-treated with mancozeb] results in increased expression of GPT protein; Resveratrol inhibits the reaction [[2-cyano-N-((ethylamino)carbonyl)-2-(methoxyimino)acetamide co-treated with mancozeb] results in increased expression of GPT protein]
|
CTD |
PMID:10641187 PMID:37009748 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
| G
|
Gpx1
|
glutathione peroxidase 1
|
decreases expression multiple interactions
|
ISO
|
mancozeb results in decreased expression of GPX1 mRNA Acetylcysteine inhibits the reaction [mancozeb results in decreased expression of GPX1 mRNA]
|
CTD |
PMID:30037311 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581
|
|
| G
|
Gsk3b
|
glycogen synthase kinase 3 beta
|
multiple interactions
|
ISO
|
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of GSK3B protein
|
CTD |
PMID:19883720 |
|
NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249
|
|
| G
|
H2ax
|
H2A.X variant histone
|
multiple interactions
|
ISO
|
[Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in increased expression of H2AX protein
|
CTD |
PMID:34830855 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
| G
|
Hdac3
|
histone deacetylase 3
|
decreases activity
|
ISO
|
mancozeb results in decreased activity of HDAC3 protein
|
CTD |
PMID:21251949 |
|
NCBI chr18:30,021,847...30,041,061
Ensembl chr18:30,021,941...30,041,025
|
|
| G
|
Hdac6
|
histone deacetylase 6
|
decreases activity
|
ISO
|
mancozeb results in decreased activity of HDAC6 protein
|
CTD |
PMID:21251949 |
|
NCBI chr X:17,222,538...17,244,373
Ensembl chr X:17,222,856...17,244,370
|
|
| G
|
Hnrnpm
|
heterogeneous nuclear ribonucleoprotein M
|
increases expression
|
ISO
|
mancozeb results in increased expression of HNRNPM protein
|
CTD |
PMID:21375462 |
|
NCBI chr 7:15,140,877...15,178,871
Ensembl chr 7:15,129,287...15,178,871
|
|
| G
|
Hspa1b
|
heat shock protein family A (Hsp70) member 1B
|
increases expression
|
ISO
|
mancozeb results in increased expression of HSPA1B mRNA
|
CTD |
PMID:36007320 |
|
NCBI chr20:3,859,756...3,863,800
Ensembl chr20:3,855,780...3,877,979
|
|
| G
|
Ifitm2
|
interferon induced transmembrane protein 2
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of IFITM2 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr 1:205,481,168...205,482,348
|
|
| G
|
Ifng
|
interferon gamma
|
multiple interactions
|
ISO
|
mancozeb affects the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of TNF protein]
|
CTD |
PMID:15742816 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
| G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
ISO
|
mancozeb inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]
|
CTD |
PMID:16112155 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
| G
|
Il2
|
interleukin 2
|
affects expression
|
ISO
|
mancozeb affects the expression of IL2 protein
|
CTD |
PMID:9012323 |
|
NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672
|
|
| G
|
Itgb3
|
integrin subunit beta 3
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of ITGB3 mRNA; mancozeb results in decreased expression of ITGB3 protein
|
CTD |
PMID:33396126 |
|
NCBI chr10:90,009,927...90,067,787
Ensembl chr10:90,009,900...90,067,800
|
|
| G
|
Kcnq2
|
potassium voltage-gated channel subfamily Q member 2
|
increases activity
|
EXP
|
mancozeb results in increased activity of KCNQ2 protein
|
CTD |
PMID:23542819 |
|
NCBI chr 3:188,572,345...188,631,391
Ensembl chr 3:188,572,926...188,631,302
|
|
| G
|
Kiss1
|
KiSS-1 metastasis-suppressor
|
affects expression
|
EXP
|
mancozeb affects the expression of KISS1 mRNA
|
CTD |
PMID:23660487 |
|
NCBI chr13:47,327,159...47,332,759
Ensembl chr13:47,327,004...47,332,906
|
|
| G
|
Ltb4r2
|
leukotriene B4 receptor 2
|
increases expression
|
ISO
|
mancozeb results in increased expression of LTB4R2 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr15:33,228,634...33,230,453
Ensembl chr15:33,228,634...33,230,453
|
|
| G
|
Map3k5
|
mitogen-activated protein kinase kinase kinase 5
|
increases expression
|
ISO
|
mancozeb results in increased expression of MAP3K5 mRNA
|
CTD |
PMID:36007320 |
|
NCBI chr 1:16,505,387...16,723,899
Ensembl chr 1:16,505,596...16,723,898
|
|
| G
|
Map3k6
|
mitogen-activated protein kinase kinase kinase 6
|
increases expression
|
ISO
|
mancozeb results in increased expression of MAP3K6 mRNA
|
CTD |
PMID:36007320 |
|
NCBI chr 5:150,724,029...150,736,113
Ensembl chr 5:150,724,216...150,736,111
|
|
| G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
ISO
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [mancozeb results in increased activity of MAPK1 protein]; mancozeb results in increased localization of and results in increased activity of MAPK1 protein
|
CTD |
PMID:21375462 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
| G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions
|
ISO
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [mancozeb results in increased activity of MAPK3 protein]; mancozeb results in increased localization of and results in increased activity of MAPK3 protein
|
CTD |
PMID:21375462 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
| G
|
Mdm2
|
MDM2 proto-oncogene
|
multiple interactions increases expression
|
ISO
|
lupeol inhibits the reaction [mancozeb results in increased expression of MDM2 mRNA]
|
CTD |
PMID:27235710 |
|
NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791
|
|
| G
|
Mt-cyb
|
mitochondrially encoded cytochrome b
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of CYTB mRNA
|
CTD |
PMID:35617905 |
|
NCBI chr MT:14,136...15,278
Ensembl chr MT:14,124...15,266
|
|
| G
|
Mt-nd3
|
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of ND3 mRNA
|
CTD |
PMID:35617905 |
|
NCBI chr MT:9,451...9,798
Ensembl chr MT:9,436...9,783
|
|
| G
|
Mt-nd4l
|
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of ND4L mRNA
|
CTD |
PMID:35617905 |
|
NCBI chr MT:9,870...10,166
Ensembl chr MT:9,855...10,151
|
|
| G
|
Mt-nd6
|
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of ND6 mRNA
|
CTD |
PMID:35617905 |
|
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,531...14,049
|
|
| G
|
Muc1
|
mucin 1, cell surface associated
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of MUC1 mRNA; mancozeb results in decreased expression of MUC1 protein
|
CTD |
PMID:33396126 |
|
NCBI chr 2:176,933,312...176,938,497
Ensembl chr 2:176,933,047...176,938,491
|
|
| G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
multiple interactions decreases expression increases expression
|
ISO EXP
|
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of MYC protein mancozeb results in decreased expression of MYC mRNA mancozeb results in increased expression of MYC protein mancozeb results in decreased expression of MYC protein alpha-Tocopherol inhibits the reaction [mancozeb results in decreased expression of MYC protein]
|
CTD |
PMID:16005924 PMID:19883720 PMID:36007320 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
| G
|
Nhlrc1
|
NHL repeat containing E3 ubiquitin protein ligase 1
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of NHLRC1 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr17:17,880,570...17,883,411
Ensembl chr17:17,880,365...17,883,620
|
|
| G
|
Nos2
|
nitric oxide synthase 2
|
increases expression multiple interactions
|
ISO
|
mancozeb results in increased expression of NOS2 mRNA Acetylcysteine inhibits the reaction [mancozeb results in increased expression of NOS2 mRNA]
|
CTD |
PMID:30037311 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
| G
|
Nox4
|
NADPH oxidase 4
|
multiple interactions increases expression
|
ISO
|
Acetylcysteine inhibits the reaction [mancozeb results in increased expression of NOX4 mRNA]
|
CTD |
PMID:30037311 |
|
NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:150,313,728...150,491,483
|
|
| G
|
Nr4a1
|
nuclear receptor subfamily 4, group A, member 1
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of NR4A1 mRNA
|
CTD |
PMID:36007320 |
|
NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041
|
|
| G
|
Odc1
|
ornithine decarboxylase 1
|
increases activity
|
ISO
|
mancozeb results in increased activity of ODC1 protein
|
CTD |
PMID:1733566 |
|
NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:46,058,463...46,065,146
|
|
| G
|
Ogg1
|
8-oxoguanine DNA glycosylase
|
multiple interactions decreases expression
|
ISO
|
lupeol inhibits the reaction [mancozeb results in decreased expression of OGG1 mRNA]
|
CTD |
PMID:27235710 |
|
NCBI chr 4:148,030,237...148,037,599
Ensembl chr 4:148,030,349...148,037,604
|
|
| G
|
Or1s2
|
olfactory receptor family 1 subfamily S member 2
|
increases expression
|
ISO
|
mancozeb results in increased expression of OR1S1 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr 1:220,338,536...220,339,483
Ensembl chr 1:220,338,530...220,339,483
|
|
| G
|
Park7
|
Parkinsonism associated deglycase
|
multiple interactions
|
ISO
|
mancozeb results in decreased activity of and results in increased oxidation of PARK7 protein
|
CTD |
PMID:36842454 |
|
NCBI chr 5:166,636,551...166,659,825
Ensembl chr 5:166,636,552...166,659,825
|
|
| G
|
Pcdhb20
|
protocadherin beta 20
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of PCDHB14 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr18:29,485,888...29,489,282
Ensembl chr18:29,454,999...29,489,427
|
|
| G
|
Prdx2
|
peroxiredoxin 2
|
increases expression
|
ISO
|
mancozeb results in increased expression of PRDX2 protein
|
CTD |
PMID:21375462 |
|
NCBI chr19:40,085,788...40,091,083
Ensembl chr19:40,084,430...40,091,006
|
|
| G
|
Prl
|
prolactin
|
multiple interactions increases expression
|
ISO
|
[mancozeb co-treated with imidacloprid] results in increased expression of PRL protein mancozeb results in increased expression of PRL mRNA
|
CTD |
PMID:24530807 PMID:33396126 |
|
NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217
|
|
| G
|
Ptges
|
prostaglandin E synthase
|
increases expression decreases expression multiple interactions
|
ISO
|
mancozeb results in increased expression of PTGES mRNA mancozeb results in decreased expression of PTGES protein lupeol inhibits the reaction [mancozeb results in increased expression of PTGES mRNA]
|
CTD |
PMID:27235710 PMID:32446389 |
|
NCBI chr 3:34,575,643...34,586,987
Ensembl chr 3:34,575,639...34,586,995
|
|
| G
|
Ptges3
|
prostaglandin E synthase 3
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of PTGES3 mRNA
|
CTD |
PMID:32446389 |
|
NCBI chr 7:1,075,230...1,092,363
Ensembl chr 7:1,075,227...1,092,695
|
|
| G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
increases expression
|
ISO
|
mancozeb results in increased expression of PTGS2 protein
|
CTD |
PMID:21375462 PMID:32446389 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
| G
|
Ptk2b
|
protein tyrosine kinase 2 beta
|
multiple interactions
|
ISO
|
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of PTK2B protein modified form
|
CTD |
PMID:19883720 |
|
NCBI chr15:44,536,275...44,656,754
Ensembl chr15:44,531,249...44,656,806
|
|
| G
|
Pvalb
|
parvalbumin
|
increases expression
|
ISO
|
mancozeb results in increased expression of PVALB protein
|
CTD |
PMID:21375462 |
|
NCBI chr 7:111,653,820...111,668,469
Ensembl chr 7:111,653,111...111,668,446
|
|
| G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
increases phosphorylation affects localization multiple interactions
|
ISO
|
mancozeb results in increased phosphorylation of RELA protein mancozeb affects the localization of RELA protein Acetylcysteine inhibits the reaction [mancozeb affects the localization of RELA protein]; lupeol inhibits the reaction [mancozeb affects the localization of RELA protein]; mancozeb inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of RELA protein]
|
CTD |
PMID:16112155 PMID:21375462 PMID:27235710 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
| G
|
S100a6
|
S100 calcium binding protein A6
|
increases expression
|
ISO
|
mancozeb results in increased expression of S100A6 protein
|
CTD |
PMID:21375462 |
|
NCBI chr 2:178,398,189...178,399,763
Ensembl chr 2:178,398,481...178,399,762
|
|
| G
|
S100a9
|
S100 calcium binding protein A9
|
increases expression
|
ISO
|
mancozeb results in increased expression of S100A9 protein
|
CTD |
PMID:21375462 |
|
NCBI chr 2:178,487,941...178,490,622
Ensembl chr 2:178,487,941...178,490,870
|
|
| G
|
Scx
|
scleraxis bHLH transcription factor
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of SCX mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr 7:110,056,897...110,059,283
Ensembl chr 7:110,054,601...110,061,438
|
|
| G
|
Sdhc
|
succinate dehydrogenase complex subunit C
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of SDHC mRNA
|
CTD |
PMID:35617905 |
|
NCBI chr13:86,077,133...86,098,025
Ensembl chr13:86,077,134...86,098,044
|
|
| G
|
Septin11
|
septin 11
|
increases expression
|
ISO
|
mancozeb results in increased expression of SEPTIN11 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr14:15,119,760...15,275,222
Ensembl chr14:15,128,951...15,275,200
|
|
| G
|
Serpinf1
|
serpin family F member 1
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of SERPINF1 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr10:60,748,504...60,760,898
Ensembl chr10:60,748,506...60,760,898
|
|
| G
|
Sirt1
|
sirtuin 1
|
decreases activity
|
ISO
|
mancozeb results in decreased activity of SIRT1 protein
|
CTD |
PMID:21251949 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000
|
|
| G
|
Sirt2
|
sirtuin 2
|
decreases activity
|
ISO
|
mancozeb results in decreased activity of SIRT2 protein
|
CTD |
PMID:21251949 |
|
NCBI chr 1:93,181,472...93,204,499
Ensembl chr 1:93,181,224...93,204,499
|
|
| G
|
Sirt3
|
sirtuin 3
|
decreases activity
|
ISO
|
mancozeb results in decreased activity of SIRT3 protein
|
CTD |
PMID:21251949 |
|
NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:205,371,710...205,394,076
|
|
| G
|
Slc14a1
|
solute carrier family 14 member 1 (Kidd blood group)
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of SLC14A1 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr18:73,840,568...73,883,925
Ensembl chr18:73,840,569...73,870,489
|
|
| G
|
Slc5a5
|
solute carrier family 5 member 5
|
multiple interactions
|
ISO
|
mancozeb inhibits the reaction [SLC5A5 protein results in increased uptake of Iodine]
|
CTD |
PMID:27979590 |
|
NCBI chr16:18,580,705...18,590,692
Ensembl chr16:18,580,705...18,590,691
|
|
| G
|
Snord82
|
small nucleolar RNA, C/D box 82
|
increases expression
|
ISO
|
mancozeb results in increased expression of SNORD82 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr 9:94,452,486...94,452,557
Ensembl chr 9:94,452,486...94,452,557
|
|
| G
|
Sod1
|
superoxide dismutase 1
|
decreases expression decreases activity
|
ISO
|
mancozeb results in decreased expression of SOD1 protein mancozeb results in decreased activity of SOD1 protein
|
CTD |
PMID:21375462 PMID:35617905 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
| G
|
Sult2b1
|
sulfotransferase family 2B member 1
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of SULT2B1 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr 1:105,336,614...105,397,744
Ensembl chr 1:105,336,614...105,397,744
|
|
| G
|
Tek
|
TEK receptor tyrosine kinase
|
increases activity
|
ISO
|
mancozeb results in increased activity of TEK protein
|
CTD |
PMID:21251949 |
|
NCBI chr 5:114,722,815...114,849,535
Ensembl chr 5:114,723,006...114,849,991
|
|
| G
|
Tgfb1i1
|
transforming growth factor beta 1 induced transcript 1
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of TGFB1I1 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr 1:192,258,992...192,265,903
Ensembl chr 1:192,258,598...192,265,903
|
|
| G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO
|
mancozeb affects the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of TNF protein] mancozeb inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; mancozeb inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; mancozeb inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of TNF protein]
|
CTD |
PMID:15742816 PMID:15893782 PMID:16112155 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
| G
|
Tp53
|
tumor protein p53
|
decreases expression increases expression multiple interactions
|
ISO
|
mancozeb results in decreased expression of TRP53 mRNA; mancozeb results in decreased expression of TRP53 protein mancozeb results in increased expression of TP53 mRNA lupeol inhibits the reaction [mancozeb results in increased expression of TP53 mRNA]
|
CTD |
PMID:22369882 PMID:27235710 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
| G
|
Tpi1
|
triosephosphate isomerase 1
|
increases expression
|
ISO
|
mancozeb results in increased expression of TPI1 protein
|
CTD |
PMID:21375462 |
|
NCBI chr 4:159,301,558...159,305,088
Ensembl chr 4:159,301,562...159,305,413
|
|
| G
|
Tpo
|
thyroid peroxidase
|
decreases activity
|
EXP
|
mancozeb results in decreased activity of TPO protein
|
CTD |
PMID:9418944 |
|
NCBI chr 6:52,425,998...52,495,793
Ensembl chr 6:52,426,010...52,495,793
|
|
| G
|
Tshb
|
thyroid stimulating hormone subunit beta
|
multiple interactions
|
ISO
|
[mancozeb co-treated with imidacloprid] results in increased expression of TSHB protein
|
CTD |
PMID:24530807 |
|
NCBI chr 2:192,913,171...192,918,054
Ensembl chr 2:192,913,171...192,942,984
|
|
| G
|
Xrcc1
|
X-ray repair cross complementing 1
|
decreases expression multiple interactions
|
ISO
|
mancozeb results in decreased expression of XRCC1 mRNA lupeol inhibits the reaction [mancozeb results in decreased expression of XRCC1 mRNA]
|
CTD |
PMID:27235710 |
|
NCBI chr 1:89,268,721...89,296,619
Ensembl chr 1:89,268,644...89,296,613
|
|
| G
|
Zfp358
|
zinc finger protein 358
|
decreases expression
|
ISO
|
mancozeb results in decreased expression of ZNF358 mRNA
|
CTD |
PMID:33396126 |
|
NCBI chr12:6,350,266...6,354,359
Ensembl chr12:6,350,067...6,354,897
|
|
|
|
| G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
multiple interactions
|
ISO
|
[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of ABCB1 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of ABCB1 protein; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of ABCB1 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of ABCB1 protein; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in increased expression of ABCB1 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in increased expression of ABCB1 protein
|
CTD |
PMID:32800223 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
| G
|
Abcc1
|
ATP binding cassette subfamily C member 1
|
multiple interactions
|
ISO
|
[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of ABCC1 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of ABCC1 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in increased expression of ABCC1 mRNA
|
CTD |
PMID:32800223 |
|
NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404
|
|
| G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
multiple interactions
|
ISO
|
[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of ABCC2 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of ABCC2 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in increased expression of ABCC2 mRNA
|
CTD |
PMID:32800223 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471
|
|
| G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
multiple interactions
|
ISO
|
[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of ABCG2 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of ABCG2 protein; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of ABCG2 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of ABCG2 protein; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in increased expression of ABCG2 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in increased expression of ABCG2 protein
|
CTD |
PMID:32800223 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493
|
|
| G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
ISO
|
[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in decreased expression of BAX mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in decreased expression of BAX protein; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in decreased expression of BAX mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in decreased expression of BAX protein; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of BAX mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of BAX protein
|
CTD |
PMID:32800223 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
| G
|
Bbc3
|
Bcl-2 binding component 3
|
multiple interactions
|
ISO
|
[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in decreased expression of BBC3 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in decreased expression of BBC3 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of BBC3 mRNA
|
CTD |
PMID:32800223 |
|
NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:86,141,603...86,150,666
|
|
| G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions
|
ISO
|
[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of BCL2 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of BCL2 protein; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of BCL2 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of BCL2 protein
|
CTD |
PMID:32800223 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
| G
|
Birc2
|
baculoviral IAP repeat-containing 2
|
multiple interactions
|
ISO
|
[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of BIRC2 mRNA
|
CTD |
PMID:32800223 |
|
NCBI chr 8:13,253,697...13,273,672
Ensembl chr 8:13,253,706...13,271,911
|
|
| G
|
Casp3
|
caspase 3
|
multiple interactions
|
ISO
|
[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in decreased expression of CASP3 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in decreased expression of CASP3 protein; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in decreased expression of CASP3 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in decreased expression of CASP3 protein
|
CTD |
PMID:32800223 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
| G
|
Casp8
|
caspase 8
|
multiple interactions
|
ISO
|
[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of CASP8 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of CASP8 protein
|
CTD |
PMID:32800223 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
| G
|
Cycs
|
cytochrome c, somatic
|
multiple interactions
|
ISO
|
[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in decreased expression of CYCS mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of CYCS mRNA
|
CTD |
PMID:32800223 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816 Ensembl chr18:80,982,668...80,984,816
|
|
| G
|
Gstm1
|
glutathione S-transferase mu 1
|
multiple interactions
|
ISO
|
[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of GSTM1 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of GSTM1 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in increased expression of GSTM1 mRNA
|
CTD |
PMID:32800223 |
|
NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:198,338,008...198,343,569
|
|
| G
|
Hdac3
|
histone deacetylase 3
|
decreases activity
|
ISO
|
polymarcine results in decreased activity of HDAC3 protein
|
CTD |
PMID:21251949 |
|
NCBI chr18:30,021,847...30,041,061
Ensembl chr18:30,021,941...30,041,025
|
|
| G
|
Hdac6
|
histone deacetylase 6
|
decreases activity
|
ISO
|
polymarcine results in decreased activity of HDAC6 protein
|
CTD |
PMID:21251949 |
|
NCBI chr X:17,222,538...17,244,373
Ensembl chr X:17,222,856...17,244,370
|
|
| G
|
Mvp
|
major vault protein
|
multiple interactions
|
ISO
|
[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in increased expression of MVP mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of MVP mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in increased expression of MVP mRNA
|
CTD |
PMID:32800223 |
|
NCBI chr 1:191,025,259...191,052,866
Ensembl chr 1:191,025,268...191,052,873
|
|
| G
|
Pmaip1
|
phorbol-12-myristate-13-acetate-induced protein 1
|
multiple interactions
|
ISO
|
[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of PMAIP1 mRNA
|
CTD |
PMID:32800223 |
|
NCBI chr18:62,255,970...62,262,384
Ensembl chr18:62,255,598...62,262,382
|
|
| G
|
Sirt1
|
sirtuin 1
|
decreases activity
|
ISO
|
polymarcine results in decreased activity of SIRT1 protein
|
CTD |
PMID:21251949 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000
|
|
| G
|
Sirt2
|
sirtuin 2
|
decreases activity
|
ISO
|
polymarcine results in decreased activity of SIRT2 protein
|
CTD |
PMID:21251949 |
|
NCBI chr 1:93,181,472...93,204,499
Ensembl chr 1:93,181,224...93,204,499
|
|
| G
|
Sirt3
|
sirtuin 3
|
decreases activity
|
ISO
|
polymarcine results in decreased activity of SIRT3 protein
|
CTD |
PMID:21251949 |
|
NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:205,371,710...205,394,076
|
|
| G
|
Slc5a5
|
solute carrier family 5 member 5
|
multiple interactions
|
ISO
|
polymarcine inhibits the reaction [SLC5A5 protein results in increased uptake of Iodine]
|
CTD |
PMID:27979590 |
|
NCBI chr16:18,580,705...18,590,692
Ensembl chr16:18,580,705...18,590,691
|
|
| G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO
|
[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of TNF mRNA
|
CTD |
PMID:32800223 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
| G
|
Tnfrsf10b
|
TNF receptor superfamily member 10b
|
multiple interactions
|
ISO
|
[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in decreased expression of TNFRSF10A mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of TNFRSF10A mRNA
|
CTD |
PMID:32800223 |
|
NCBI chr15:51,249,883...51,278,091
Ensembl chr15:51,250,112...51,278,082
|
|
| G
|
Tp53
|
tumor protein p53
|
multiple interactions
|
ISO
|
[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Cisplatin] which results in decreased expression of TP53 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in decreased expression of TP53 mRNA; [[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Temozolomide] which results in decreased expression of TP53 mRNA
|
CTD |
PMID:32800223 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
| G
|
Xiap
|
X-linked inhibitor of apoptosis
|
multiple interactions
|
ISO
|
[[Chlorpyrifos co-treated with decamethrin co-treated with polymarcine co-treated with Glyphosate] results in decreased susceptibility to Fluorouracil] which results in increased expression of XIAP mRNA
|
CTD |
PMID:32800223 |
|
NCBI chr X:125,756,107...125,803,979
Ensembl chr X:125,737,971...125,803,978
|
|
|
|
| G
|
Park7
|
Parkinsonism associated deglycase
|
decreases activity
|
ISO
|
propineb results in decreased activity of PARK7 protein
|
CTD |
PMID:36842454 |
|
NCBI chr 5:166,636,551...166,659,825
Ensembl chr 5:166,636,552...166,659,825
|
|
|
|
| G
|
Adipoq
|
adiponectin, C1Q and collagen domain containing
|
multiple interactions
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]; zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]] zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]
|
CTD |
PMID:20052772 PMID:20861358 |
|
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169
|
|
| G
|
Agt
|
angiotensinogen
|
multiple interactions
|
ISO
|
[zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]]
|
CTD |
PMID:20523338 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944
|
|
| G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [olprinone results in increased activity of AKT1 protein]
|
CTD |
PMID:19387321 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
| G
|
Alad
|
aminolevulinate dehydratase
|
affects abundance
|
ISO
|
ALAD gene SNP affects the abundance of zinc protoporphyrin
|
CTD |
PMID:25963508 |
|
NCBI chr 5:80,977,562...80,987,901
Ensembl chr 5:80,977,562...80,988,041
|
|
| G
|
Alb
|
albumin
|
multiple interactions
|
ISO
|
ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; ALB protein inhibits the reaction [zinc protoporphyrin results in increased expression of HMOX1 protein] zinc protoporphyrin inhibits the reaction [ALB protein results in increased expression of HMOX1 protein]; zinc protoporphyrin promotes the reaction [ALB protein results in increased expression of TIMP1 protein]
|
CTD |
PMID:19376148 PMID:21163135 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
|
|
| G
|
Alms1
|
ALMS1, centrosome and basal body associated protein
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of ALMS1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 4:119,683,085...119,783,471
Ensembl chr 4:119,683,076...119,783,471
|
|
| G
|
Ap2a1
|
adaptor related protein complex 2 subunit alpha 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of AP2A1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 1:104,520,789...104,550,655
Ensembl chr 1:104,520,792...104,550,655
|
|
| G
|
Ap3d1
|
adaptor related protein complex 3 subunit delta 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of AP3D1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 7:9,620,909...9,656,350
Ensembl chr 7:9,620,968...9,656,342
|
|
| G
|
Asf1a
|
anti-silencing function 1A histone chaperone
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of ASF1A mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr20:33,436,632...33,451,478
Ensembl chr20:33,436,707...33,449,639
|
|
| G
|
Bach1
|
BTB domain and CNC homolog 1
|
multiple interactions
|
EXP
|
zinc protoporphyrin affects the reaction [BACH1 protein affects the reaction [Doxorubicin results in decreased expression of NFE2L2 mRNA]]; zinc protoporphyrin affects the reaction [BACH1 protein affects the reaction [Doxorubicin results in decreased expression of NFE2L2 protein]]; zinc protoporphyrin affects the reaction [BACH1 protein affects the reaction [Doxorubicin results in increased expression of PTGS2 mRNA]]; zinc protoporphyrin affects the reaction [BACH1 protein affects the reaction [Doxorubicin results in increased expression of PTGS2 protein]]
|
CTD |
PMID:38573338 |
|
NCBI chr11:40,425,721...40,461,118
Ensembl chr11:40,425,664...40,461,277
|
|
| G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
multiple interactions
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; zinc protoporphyrin inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in increased expression of BAX protein]] zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in increased expression of BAX mRNA]] zinc protoporphyrin inhibits the reaction [Cisplatin results in increased expression of BAX protein]
|
CTD |
PMID:22763982 PMID:27523796 PMID:27815112 PMID:32621855 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
| G
|
Bcl2
|
BCL2, apoptosis regulator
|
multiple interactions
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; zinc protoporphyrin inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]] zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]]
|
CTD |
PMID:22763982 PMID:27523796 PMID:32621855 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
| G
|
Bcl2l1
|
Bcl2-like 1
|
multiple interactions increases expression
|
EXP ISO
|
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of BCL2L1 protein] zinc protoporphyrin results in increased expression of BCL2L1 protein
|
CTD |
PMID:20357190 PMID:27829220 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907 Ensembl chr 1:161,745,540...161,764,907
|
|
| G
|
Bcl2l11
|
Bcl2-like 11
|
increases expression
|
ISO
|
zinc protoporphyrin results in increased expression of BCL2L11 protein
|
CTD |
PMID:27829220 |
|
NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695
|
|
| G
|
Bglap
|
bone gamma-carboxyglutamate protein
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [15-deoxyprostaglandin J2 results in decreased expression of BGLAP mRNA]; zinc protoporphyrin inhibits the reaction [Hemin results in decreased expression of BGLAP mRNA]
|
CTD |
PMID:20020468 |
|
NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318
|
|
| G
|
Birc3
|
baculoviral IAP repeat-containing 3
|
multiple interactions
|
ISO
|
zinc protoporphyrin analog inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of BIRC3 protein]
|
CTD |
PMID:18508827 |
|
NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:13,285,703...13,298,590
|
|
| G
|
Calca
|
calcitonin-related polypeptide alpha
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [monophosphoryl lipid A results in increased expression of CALCA mRNA]
|
CTD |
PMID:11738242 |
|
NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:178,312,638...178,317,529
|
|
| G
|
Cand1
|
cullin-associated and neddylation-dissociated 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of CAND1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 7:56,566,765...56,604,653
Ensembl chr 7:56,551,394...56,604,655
|
|
| G
|
Casp1
|
caspase 1
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased cleavage of CASP1 protein]]
|
CTD |
PMID:36858639 |
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275
|
|
| G
|
Casp3
|
caspase 3
|
multiple interactions increases cleavage decreases activity
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [[Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [Resveratrol inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]]; zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]]; zinc protoporphyrin promotes the reaction [T-2 Toxin results in increased activity of CASP3 protein] zinc protoporphyrin results in increased cleavage of CASP3 protein zinc protoporphyrin inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [Curcumin inhibits the reaction [quinocetone results in increased activity of CASP3 protein]]; zinc protoporphyrin inhibits the reaction [FASLG protein results in increased activity of CASP3 protein]; zinc protoporphyrin inhibits the reaction [FASLG protein results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]]; zinc protoporphyrin promotes the reaction [arsenic trioxide results in increased activity of CASP3 protein]; zinc protoporphyrin promotes the reaction [quinocetone results in increased activity of CASP3 protein] zinc protoporphyrin inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in decreased expression of CASP3 protein]; zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in increased expression of CASP3 mRNA]]; zinc protoporphyrin promotes the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased cleavage of CASP3 protein]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased cleavage of CASP3 protein] zinc protoporphyrin results in decreased activity of CASP3 protein
|
CTD |
PMID:16051694 PMID:17928392 PMID:20357190 PMID:21295052 PMID:22763982 PMID:25003661 PMID:26747958 PMID:27375190 PMID:27815112 PMID:28025122 PMID:29432840 PMID:30261164 PMID:32621855 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
| G
|
Casp8
|
caspase 8
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [FASLG protein results in increased activity of CASP8 protein]
|
CTD |
PMID:16051694 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
| G
|
Casp9
|
caspase 9
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Curcumin inhibits the reaction [quinocetone results in increased activity of CASP9 protein]]; zinc protoporphyrin promotes the reaction [quinocetone results in increased activity of CASP9 protein] zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased activity of CASP9 protein]]; zinc protoporphyrin promotes the reaction [T-2 Toxin results in increased activity of CASP9 protein]
|
CTD |
PMID:27375190 PMID:29432840 PMID:30261164 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
| G
|
Cat
|
catalase
|
multiple interactions
|
EXP ISO
|
zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in decreased expression of CAT protein]] zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]]
|
CTD |
PMID:32621855 PMID:35691465 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
| G
|
Ccdc6
|
coiled-coil domain containing 6
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of CCDC6 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr20:18,431,243...18,527,227
Ensembl chr20:18,431,243...18,527,227
|
|
| G
|
Ccl2
|
C-C motif chemokine ligand 2
|
multiple interactions
|
EXP ISO
|
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in decreased expression of CCL2 protein]; zinc protoporphyrin promotes the reaction [Indomethacin results in increased expression of CCL2 mRNA] zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]]
|
CTD |
PMID:20357190 PMID:23892052 PMID:35691465 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
| G
|
Ccr7
|
C-C motif chemokine receptor 7
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CCR7 mRNA]
|
CTD |
PMID:33049506 |
|
NCBI chr10:84,594,399...84,604,514
Ensembl chr10:84,593,594...84,604,501
|
|
| G
|
Cd40
|
CD40 molecule
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA]
|
CTD |
PMID:33049506 |
|
NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:174,209,719...174,224,847
|
|
| G
|
Cd80
|
Cd80 molecule
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 mRNA]
|
CTD |
PMID:33049506 |
|
NCBI chr11:75,760,073...75,798,978
Ensembl chr11:75,760,147...75,797,540
|
|
| G
|
Cd83
|
CD83 molecule
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CD83 mRNA]
|
CTD |
PMID:33049506 |
|
NCBI chr17:21,093,281...21,113,223
Ensembl chr17:21,093,281...21,113,047
|
|
| G
|
Cd86
|
CD86 molecule
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 mRNA]
|
CTD |
PMID:33049506 |
|
NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361
|
|
| G
|
Cdk13
|
cyclin-dependent kinase 13
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of CDK13 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr17:51,945,975...52,040,218
Ensembl chr17:51,946,701...52,037,257
|
|
| G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
multiple interactions
|
ISO
|
zinc protoporphyrin analog inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of and affects the localization of CDKN1A protein]
|
CTD |
PMID:18508827 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
| G
|
Chd7
|
chromodomain helicase DNA binding protein 7
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of CHD7 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 5:26,609,245...26,792,736
Ensembl chr 5:26,609,407...26,792,734
|
|
| G
|
Cmbl
|
carboxymethylenebutenolidase homolog
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of CMBL mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 2:84,280,128...84,301,878
Ensembl chr 2:84,242,512...84,301,880
|
|
| G
|
Cxcl1
|
C-X-C motif chemokine ligand 1
|
increases expression
|
EXP
|
zinc protoporphyrin results in increased expression of CXCL1 mRNA
|
CTD |
PMID:25780291 |
|
NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811
|
|
| G
|
Cxcl10
|
C-X-C motif chemokine ligand 10
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]
|
CTD |
PMID:20861358 |
|
NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261
|
|
| G
|
Cxcl2
|
C-X-C motif chemokine ligand 2
|
increases expression
|
EXP
|
zinc protoporphyrin results in increased expression of CXCL2 mRNA
|
CTD |
PMID:25780291 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255
|
|
| G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
multiple interactions
|
EXP
|
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of CYP1A1 protein
|
CTD |
PMID:26747958 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
| G
|
Cyp1a2
|
cytochrome P450, family 1, subfamily a, polypeptide 2
|
multiple interactions
|
EXP
|
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of CYP1A2 protein
|
CTD |
PMID:26747958 |
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149
|
|
| G
|
Cyp2b1
|
cytochrome P450, family 2, subfamily b, polypeptide 1
|
multiple interactions
|
EXP
|
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of CYP2B1 protein
|
CTD |
PMID:26747958 |
|
NCBI chr 1:90,646,098...90,669,762
|
|
| G
|
Cyp2e1
|
cytochrome P450, family 2, subfamily e, polypeptide 1
|
multiple interactions
|
EXP ISO
|
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of CYP2E1 mRNA; [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of CYP2E1 protein; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of CYP2E1 mRNA]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of CYP2E1 protein] zinc protoporphyrin inhibits the reaction [Quercetin inhibits the reaction [Ethanol results in increased expression of and results in increased activity of CYP2E1 protein]]; zinc protoporphyrin inhibits the reaction [tricarbonyldichlororuthenium (II) dimer inhibits the reaction [Ethanol results in increased activity of CYP2E1 protein]]
|
CTD |
PMID:19325051 PMID:26747958 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495
|
|
| G
|
Dcun1d1
|
defective in cullin neddylation 1 domain containing 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of DCUN1D1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 2:120,649,445...120,700,879
Ensembl chr 2:120,649,445...120,700,870
|
|
| G
|
Ddit3
|
DNA-damage inducible transcript 3
|
multiple interactions
|
EXP
|
zinc protoporphyrin promotes the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of DDIT3 protein]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of DDIT3 protein]
|
CTD |
PMID:26747958 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
|
|
| G
|
Dhx29
|
DExH-box helicase 29
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of DHX29 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 2:46,293,901...46,344,652
Ensembl chr 2:46,293,677...46,344,948
|
|
| G
|
Dusp10
|
dual specificity phosphatase 10
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [andrographolide results in increased expression of DUSP10 mRNA]; zinc protoporphyrin inhibits the reaction [andrographolide results in increased expression of DUSP10 protein]
|
CTD |
PMID:29165873 |
|
NCBI chr13:98,145,317...98,183,304
Ensembl chr13:98,145,893...98,183,304
|
|
| G
|
Eif2ak3
|
eukaryotic translation initiation factor 2 alpha kinase 3
|
multiple interactions
|
EXP
|
zinc protoporphyrin promotes the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased phosphorylation of EIF2AK3 protein]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased phosphorylation of EIF2AK3 protein]
|
CTD |
PMID:26747958 |
|
NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:104,363,833...104,425,268
|
|
| G
|
Eml4
|
EMAP like 4
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of EML4 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 6:16,972,054...17,087,365
Ensembl chr 6:16,972,075...17,087,439
|
|
| G
|
F2
|
coagulation factor II, thrombin
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [tricarbonyldichlororuthenium (II) dimer inhibits the reaction [F2 protein results in increased expression of PTGS2 protein]]; zinc protoporphyrin inhibits the reaction [tricarbonyldichlororuthenium (II) dimer inhibits the reaction [F2 protein results in increased secretion of Dinoprostone]]
|
CTD |
PMID:26385185 |
|
NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246
|
|
| G
|
Faslg
|
Fas ligand
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [FASLG protein results in increased activity of CASP3 protein]; zinc protoporphyrin inhibits the reaction [FASLG protein results in increased activity of CASP8 protein]; zinc protoporphyrin inhibits the reaction [FASLG protein results in increased cleavage of CASP3 protein]
|
CTD |
PMID:16051694 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503
|
|
| G
|
Fbxw12
|
F-box and WD repeat domain containing 12
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of FBXW12 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 8:118,660,777...118,680,565
Ensembl chr 8:118,660,605...118,680,572
|
|
| G
|
Fgfr1
|
Fibroblast growth factor receptor 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of FGFR1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr16:73,194,631...73,249,855
Ensembl chr16:73,194,631...73,249,855
|
|
| G
|
Flt1
|
Fms related receptor tyrosine kinase 1
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Diazoxide inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]]
|
CTD |
PMID:25371888 |
|
NCBI chr12:12,333,050...12,504,750
Ensembl chr12:12,333,430...12,504,750
|
|
| G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
increases expression
|
ISO
|
zinc protoporphyrin results in increased expression of FOS mRNA
|
CTD |
PMID:10381381 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
| G
|
Fut4
|
fucosyltransferase 4
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of FUT4 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 8:19,868,178...19,872,139
Ensembl chr 8:19,868,079...19,872,436
|
|
| G
|
Glul
|
glutamate-ammonia ligase
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [Resveratrol inhibits the reaction [Ammonia results in decreased activity of GLUL protein]]; zinc protoporphyrin inhibits the reaction [Resveratrol results in increased activity of GLUL protein]
|
CTD |
PMID:26318273 |
|
NCBI chr13:68,519,500...68,585,554
Ensembl chr13:68,576,067...68,585,520
|
|
| G
|
Gpr132
|
G protein-coupled receptor 132
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of GPR132 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 6:137,745,142...137,763,037
Ensembl chr 6:137,745,241...137,763,157
|
|
| G
|
Gpx1
|
glutathione peroxidase 1
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of GPX1 protein]
|
CTD |
PMID:36696656 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581
|
|
| G
|
Gpx4
|
glutathione peroxidase 4
|
multiple interactions
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of GPX4 protein] zinc protoporphyrin inhibits the reaction [Cadmium results in decreased expression of GPX4 protein]
|
CTD |
PMID:36696656 PMID:39025289 |
|
NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:10,300,832...10,303,629
|
|
| G
|
Gsdmd
|
gasdermin D
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased cleavage of GSDMD protein]]
|
CTD |
PMID:36858639 |
|
NCBI chr 7:109,423,209...109,427,771
Ensembl chr 7:109,422,910...109,430,722
|
|
| G
|
Gucy1a1
|
guanylate cyclase 1 soluble subunit alpha 1
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]
|
CTD |
PMID:19466990 |
|
NCBI chr 2:169,716,684...169,780,360
Ensembl chr 2:169,716,709...169,779,737
|
|
| G
|
Gucy1b1
|
guanylate cyclase 1 soluble subunit beta 1
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]
|
CTD |
PMID:19466990 |
|
NCBI chr 2:169,646,897...169,697,060
Ensembl chr 2:169,646,898...169,696,987
|
|
| G
|
Haus2
|
HAUS augmin like complex subunit 2
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of HAUS2 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 3:128,006,894...128,019,730
Ensembl chr 3:128,006,932...128,019,729
|
|
| G
|
Havcr1
|
hepatitis A virus cellular receptor 1
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [Cadmium results in increased expression of HAVCR1 protein]
|
CTD |
PMID:39025289 |
|
NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,619,897...31,653,268
|
|
| G
|
Hfe
|
homeostatic iron regulator
|
affects abundance
|
ISO
|
HFE gene polymorphism affects the abundance of zinc protoporphyrin
|
CTD |
PMID:25963508 |
|
NCBI chr17:41,841,302...41,849,359
Ensembl chr17:41,841,252...41,851,208
|
|
| G
|
Hif1a
|
hypoxia inducible factor 1 subunit alpha
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [HIF1A protein results in increased activity of SOD2 protein]
|
CTD |
PMID:17066447 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323
|
|
| G
|
Hmgb1
|
high mobility group box 1
|
multiple interactions
|
EXP ISO
|
zinc protoporphyrin promotes the reaction [lead acetate results in increased expression of HMGB1 mRNA] zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased expression of HMGB1 protein]]
|
CTD |
PMID:29447957 PMID:30261164 |
|
NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327 Ensembl chr12:39,039,050...39,041,327
|
|
| G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions decreases expression increases expression affects expression decreases activity
|
ISO EXP
|
[zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [cobaltiprotoporphyrin results in increased expression of TP53 protein]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] which results in increased susceptibility to 2-butenal; [zinc protoporphyrin results in decreased activity of HMOX1 protein] which results in increased susceptibility to Arsenic Trioxide; [zinc protoporphyrin results in decreased activity of HMOX1] which results in decreased susceptibility to peoniflorin; zinc protoporphyrin analog inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron]; zinc protoporphyrin inhibits the reaction [[cobaltiprotoporphyrin results in increased expression of HMOX1 protein] inhibits the reaction [Ethanol results in decreased abundance of Glutathione]]; zinc protoporphyrin inhibits the reaction [[cobaltiprotoporphyrin results in increased expression of HMOX1 protein] inhibits the reaction [Ethanol results in increased abundance of Malondialdehyde]]; zinc protoporphyrin inhibits the reaction [[cobaltiprotoporphyrin results in increased expression of HMOX1 protein] which results in decreased susceptibility to Ethanol]; zinc protoporphyrin inhibits the reaction [ALB protein results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Cilostazol results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [Cilostazol results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased activity of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Dexmedetomidine promotes the reaction [Ropivacaine results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased abundance of Reactive Oxygen Species]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]]; zinc protoporphyrin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of HMOX1 protein]; zinc protoporphyrin promotes the reaction [Arsenic Trioxide results in increased expression of HMOX1 protein]; zinc protoporphyrin results in decreased expression of and results in decreased activity of HMOX1 protein; zinc protoporphyrin results in increased expression of and results in decreased activity of HMOX1 protein zinc protoporphyrin results in decreased expression of HMOX1 mRNA; zinc protoporphyrin results in decreased expression of HMOX1 protein zinc protoporphyrin results in increased expression of HMOX1 protein zinc protoporphyrin affects the expression of HMOX1 mRNA; zinc protoporphyrin affects the expression of HMOX1 protein zinc protoporphyrin results in decreased activity of HMOX1; zinc protoporphyrin results in decreased activity of HMOX1 protein zinc protoporphyrin results in increased expression of HMOX1 mRNA; zinc protoporphyrin results in increased expression of HMOX1 protein [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of HMOX1 mRNA; [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with zinc protoporphyrin] results in increased expression of HMOX1 mRNA; [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [chrysin inhibits the reaction [tert-Butylhydroperoxide results in increased chemical synthesis of Reactive Oxygen Species]]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [Resveratrol results in increased abundance of Glutathione]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] which results in decreased susceptibility to Resveratrol; Hemin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]]; Hemin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Cadmium results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased activity of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin promotes the reaction [Glucose results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides]; zinc protoporphyrin inhibits the reaction [lead acetate results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [olprinone results in increased activity of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [perflexane promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of and results in increased activity of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Propofol inhibits the reaction [Glucose results in decreased activity of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Propofol promotes the reaction [Glucose results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Sildenafil Citrate results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [Sildenafil Citrate results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Tadalafil promotes the reaction [Cisplatin results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of HMOX1 protein] [zinc protoporphyrin co-treated with Hemin] results in increased expression of HMOX1 mRNA; [zinc protoporphyrin results in increased expression of HMOX1 protein] inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; ALB protein inhibits the reaction [zinc protoporphyrin results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [8-oxoberberine promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone] results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Cisplatin results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides]; zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Resveratrol inhibits the reaction [Doxorubicin results in decreased expression of and results in decreased activity of HMOX1 protein]]
|
CTD |
PMID:7524564 PMID:12352873 PMID:14649057 PMID:15602829 PMID:16462769 PMID:17292349 PMID:17627722 PMID:17928392 PMID:18006204 PMID:18042465 PMID:18073186 PMID:18508827 PMID:19019021 PMID:19136476 PMID:19376148 PMID:19387321 PMID:19608869 PMID:20052772 PMID:20056245 PMID:20131233 PMID:20357190 PMID:20360627 PMID:20523338 PMID:21163135 PMID:21238556 PMID:21253390 PMID:21295052 PMID:21315065 PMID:21327864 PMID:21382476 PMID:21448202 PMID:21518603 PMID:21660147 PMID:21690482 PMID:21925249 PMID:22118543 PMID:22763982 PMID:22859313 PMID:22864849 PMID:23403272 PMID:23525258 PMID:23691207 PMID:23704825 PMID:24003391 PMID:24810525 PMID:25780291 PMID:25824035 PMID:26747958 PMID:27523796 PMID:27815112 PMID:27829220 PMID:27830717 PMID:29447957 PMID:31356851 PMID:32621855 PMID:33049506 PMID:34029560 PMID:35691465 PMID:36696656 PMID:36858639 PMID:39025289 More...
|
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
| G
|
Hmox2
|
heme oxygenase 2
|
decreases activity decreases expression
|
ISO EXP
|
zinc protoporphyrin results in decreased activity of HMOX2 protein zinc protoporphyrin results in decreased expression of HMOX2 protein
|
CTD |
PMID:21448202 PMID:25824035 |
|
NCBI chr10:11,303,512...11,337,640
Ensembl chr10:11,303,512...11,318,800
|
|
| G
|
Hp1bp3
|
heterochromatin protein 1, binding protein 3
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of HP1BP3 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 5:155,719,109...155,746,329
Ensembl chr 5:155,719,115...155,746,325
|
|
| G
|
Hsd11b1
|
hydroxysteroid 11-beta dehydrogenase 1
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased expression of HSD11B1 mRNA]]
|
CTD |
PMID:27523796 |
|
NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432
|
|
| G
|
Icam1
|
intercellular adhesion molecule 1
|
multiple interactions
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]] zinc protoporphyrin promotes the reaction [Indomethacin results in increased expression of ICAM1 mRNA] zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA]
|
CTD |
PMID:19608869 PMID:23892052 PMID:33049506 |
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
| G
|
Ifnb1
|
interferon beta 1
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]]
|
CTD |
PMID:20861358 |
|
NCBI chr 5:108,066,650...108,067,487
Ensembl chr 5:108,066,650...108,067,487
|
|
| G
|
Ifng
|
interferon gamma
|
multiple interactions increases expression
|
EXP
|
zinc protoporphyrin inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased expression of HMOX1 protein] zinc protoporphyrin results in increased expression of IFNG mRNA
|
CTD |
PMID:21295052 PMID:25780291 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
| G
|
Il10
|
interleukin 10
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of IL10 mRNA]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of IL10 protein]; zinc protoporphyrin inhibits the reaction [perflexane inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of IL10 protein]]
|
CTD |
PMID:20056245 PMID:20360627 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
| G
|
Il12b
|
interleukin 12B
|
multiple interactions
|
ISO
|
zinc protoporphyrin promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B mRNA]]
|
CTD |
PMID:33049506 |
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194
|
|
| G
|
Il18
|
interleukin 18
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of IL18 protein]]; zinc protoporphyrin inhibits the reaction [Hemin results in decreased susceptibility to IL18 protein]
|
CTD |
PMID:18215737 PMID:36858639 |
|
NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286
|
|
| G
|
Il1b
|
interleukin 1 beta
|
multiple interactions increases expression
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [Cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of IL1B protein]] zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]]; zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]] zinc protoporphyrin results in increased expression of IL1B mRNA zinc protoporphyrin inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased expression of HMOX1 protein]; zinc protoporphyrin promotes the reaction [Indomethacin results in increased expression of IL1B mRNA]
|
CTD |
PMID:20131233 PMID:21295052 PMID:23892052 PMID:25780291 PMID:27523796 PMID:30261164 PMID:35691465 PMID:36858639 More...
|
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
| G
|
Il23a
|
interleukin 23 subunit alpha
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased expression of IL23A mRNA]]; zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL23A protein]]
|
CTD |
PMID:33049506 |
|
NCBI chr 7:1,306,320...1,308,434
Ensembl chr 7:1,306,320...1,308,434
|
|
| G
|
Il6
|
interleukin 6
|
multiple interactions increases expression
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of IL6 protein]] zinc protoporphyrin results in increased expression of IL6 mRNA zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; zinc protoporphyrin inhibits the reaction [manganese chloride promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]
|
CTD |
PMID:19608869 PMID:20131233 PMID:21963524 PMID:25780291 PMID:27523796 PMID:30261164 PMID:33049506 PMID:35691465 More...
|
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
| G
|
Inpp5d
|
inositol polyphosphate-5-phosphatase D
|
decreases expression
|
EXP
|
zinc protoporphyrin results in decreased expression of INPP5D protein
|
CTD |
PMID:25780291 |
|
NCBI chr 9:95,735,533...95,840,584
Ensembl chr 9:95,735,530...95,840,589
|
|
| G
|
Irak1
|
interleukin-1 receptor-associated kinase 1
|
multiple interactions
|
EXP
|
zinc protoporphyrin promotes the reaction [IRAK1 protein binds to MYD88 protein]
|
CTD |
PMID:25780291 |
|
NCBI chr X:156,919,927...156,929,825
Ensembl chr X:156,920,081...156,929,825
|
|
| G
|
Irak3
|
interleukin-1 receptor-associated kinase 3
|
decreases expression
|
EXP
|
zinc protoporphyrin results in decreased expression of IRAK3 protein
|
CTD |
PMID:25780291 |
|
NCBI chr 7:57,538,522...57,600,166
Ensembl chr 7:57,539,557...57,598,706
|
|
| G
|
Itgam
|
integrin subunit alpha M
|
increases expression
|
ISO
|
zinc protoporphyrin results in increased expression of ITGAM protein
|
CTD |
PMID:22118543 |
|
NCBI chr 1:192,089,496...192,139,947
Ensembl chr 1:192,089,542...192,139,943
|
|
| G
|
Jun
|
Jun proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions increases expression
|
ISO
|
zinc protoporphyrin promotes the reaction [arsenic trioxide results in increased expression of JUN protein] zinc protoporphyrin results in increased expression of JUN protein
|
CTD |
PMID:27829220 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285
|
|
| G
|
Kcnab1
|
potassium voltage-gated channel subfamily A regulatory beta subunit 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of KCNAB1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 2:151,446,975...151,913,636
Ensembl chr 2:151,446,947...151,913,636
|
|
| G
|
Kctd20
|
potassium channel tetramerization domain containing 20
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of KCTD20 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr20:7,017,480...7,034,440
Ensembl chr20:7,017,502...7,034,441
|
|
| G
|
Kidins220
|
kinase D-interacting substrate 220
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of KIDINS220 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 6:47,346,790...47,435,599
Ensembl chr 6:47,346,832...47,431,865
|
|
| G
|
Kitlg
|
KIT ligand
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of KITLG mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 7:36,782,621...36,863,796
Ensembl chr 7:36,782,638...36,863,793
|
|
| G
|
Kras
|
KRAS proto-oncogene, GTPase
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of KRAS mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320
|
|
| G
|
Larp1b
|
La ribonucleoprotein 1B
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of LARP1B mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 2:125,860,935...125,897,189
Ensembl chr 2:125,863,997...125,897,189
|
|
| G
|
Lcn2
|
lipocalin 2
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [Cadmium results in increased expression of LCN2 protein]
|
CTD |
PMID:39025289 |
|
NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:36,078,436...36,081,842
|
|
| G
|
Ldha
|
lactate dehydrogenase A
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Dexmedetomidine inhibits the reaction [Ropivacaine results in increased expression of LDHA protein]]
|
CTD |
PMID:36858639 |
|
NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:106,502,182...106,517,521
|
|
| G
|
Lnx1
|
ligand of numb-protein X 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of LNX1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr14:33,868,517...33,971,217
Ensembl chr14:33,868,571...33,971,217
|
|
| G
|
Lyrm7
|
LYR motif containing 7
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of LYRM7 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr10:39,465,019...39,483,973
Ensembl chr10:39,465,036...39,484,240
|
|
| G
|
Macf1
|
microtubule-actin crosslinking factor 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of MACF1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 5:140,908,829...141,234,127
Ensembl chr 5:140,908,837...141,233,890
|
|
| G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions increases phosphorylation
|
ISO
|
[zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]] zinc protoporphyrin results in increased phosphorylation of MAPK1 protein zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]]; zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]; zinc protoporphyrin promotes the reaction [lipoteichoic acid results in increased phosphorylation of MAPK1 protein]; zinc protoporphyrin promotes the reaction [Peptidoglycan results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:19376148 PMID:20523338 PMID:27523796 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
| G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions increases phosphorylation
|
ISO
|
[zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]] zinc protoporphyrin results in increased phosphorylation of MAPK3 protein zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]]; zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]; zinc protoporphyrin promotes the reaction [lipoteichoic acid results in increased phosphorylation of MAPK3 protein]; zinc protoporphyrin promotes the reaction [Peptidoglycan results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:19376148 PMID:20523338 PMID:27523796 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
| G
|
Mark2
|
microtubule affinity regulating kinase 2
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of MARK2 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 1:213,890,213...213,955,417
Ensembl chr 1:213,890,213...213,955,149
|
|
| G
|
Mfn1
|
mitofusin 1
|
multiple interactions
|
EXP
|
Hemin inhibits the reaction [zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]]; Hemin inhibits the reaction [zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]]; zinc protoporphyrin inhibits the reaction [Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]]; zinc protoporphyrin inhibits the reaction [Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]]; zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]; zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]
|
CTD |
PMID:27830717 |
|
NCBI chr 2:117,240,525...117,288,017
Ensembl chr 2:117,241,759...117,290,190
|
|
| G
|
Mllt3
|
MLLT3, super elongation complex subunit
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of MLLT3 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 5:107,305,008...107,561,352
Ensembl chr 5:107,284,766...107,561,352
|
|
| G
|
Mmp2
|
matrix metallopeptidase 2
|
affects expression multiple interactions
|
EXP ISO
|
zinc protoporphyrin affects the expression of MMP2 zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP2 mRNA]; zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP2 protein]
|
CTD |
PMID:23704825 PMID:30076913 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
| G
|
Mmp9
|
matrix metallopeptidase 9
|
multiple interactions
|
ISO
|
zinc protoporphyrin promotes the reaction [arsenic trioxide results in increased expression of MMP9 protein] zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP9 mRNA]; zinc protoporphyrin inhibits the reaction [fisetin results in decreased expression of MMP9 protein]
|
CTD |
PMID:27829220 PMID:30076913 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
| G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
EXP
|
zinc protoporphyrin inhibits the reaction [perflexane inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased activity of MPO protein]]; zinc protoporphyrin promotes the reaction [Indomethacin results in increased activity of MPO protein]; zinc protoporphyrin promotes the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]
|
CTD |
PMID:17292349 PMID:20360627 PMID:23892052 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
| G
|
Myd88
|
MYD88, innate immune signal transduction adaptor
|
multiple interactions
|
EXP
|
zinc protoporphyrin promotes the reaction [IRAK1 protein binds to MYD88 protein]; zinc protoporphyrin promotes the reaction [TLR2 protein binds to MYD88 protein]; zinc protoporphyrin promotes the reaction [TLR4 protein binds to MYD88 protein]; zinc protoporphyrin promotes the reaction [TRAF6 protein binds to MYD88 protein]
|
CTD |
PMID:25780291 |
|
NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230
|
|
| G
|
Ncf1
|
neutrophil cytosolic factor 1
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [SRC protein binds to NCF1 protein]]]
|
CTD |
PMID:19608869 |
|
NCBI chr12:28,121,816...28,131,080
Ensembl chr12:28,121,366...28,131,079
|
|
| G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions affects expression
|
EXP
|
zinc protoporphyrin affects the reaction [BACH1 protein affects the reaction [Doxorubicin results in decreased expression of NFE2L2 mRNA]]; zinc protoporphyrin affects the reaction [BACH1 protein affects the reaction [Doxorubicin results in decreased expression of NFE2L2 protein]]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of NFE2L2 protein] zinc protoporphyrin affects the expression of NFE2L2 mRNA; zinc protoporphyrin affects the expression of NFE2L2 protein
|
CTD |
PMID:23704825 PMID:25824035 PMID:38573338 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
| G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]]
|
CTD |
PMID:21925249 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
|
|
| G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [cilostazol results in increased expression of NFKBIA protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of NFKBIA protein] zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]]
|
CTD |
PMID:20131233 PMID:21925249 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
| G
|
Nos1
|
nitric oxide synthase 1
|
multiple interactions
|
EXP
|
[Sildenafil Citrate co-treated with zinc protoporphyrin] results in increased expression of NOS1 mRNA
|
CTD |
PMID:17627722 |
|
NCBI chr12:44,276,011...44,456,371
Ensembl chr12:44,287,614...44,371,837
|
|
| G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions
|
ISO EXP
|
[zinc protoporphyrin results in increased expression of HMOX1 protein] inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; lactacystin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; lactacystin inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; lactacystin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; pyrazolanthrone inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; pyrazolanthrone inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; pyrazolanthrone inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]; zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of NOS2 mRNA; [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of NOS2 protein; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in decreased expression of NOS2 protein]; zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in increased expression of NOS2 mRNA]]; zinc protoporphyrin inhibits the reaction [tricarbonyldichlororuthenium (II) dimer inhibits the reaction [Ethanol results in increased expression of NOS2 mRNA]]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of NOS2 mRNA]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of NOS2 protein]
|
CTD |
PMID:19376148 PMID:20357190 PMID:21925249 PMID:26460608 PMID:26747958 PMID:32621855 More...
|
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
| G
|
Pde4dip
|
phosphodiesterase 4D interacting protein
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of PDE4DIP mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 2:187,982,002...188,178,937
Ensembl chr 2:187,981,878...188,178,869
|
|
| G
|
Pgf
|
placental growth factor
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of PGF mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 6:110,547,165...110,557,747
Ensembl chr 6:110,547,153...110,557,747
|
|
| G
|
Polr3k
|
RNA polymerase III subunit K
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of POLR3K mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 3:189,360,349...189,364,546
Ensembl chr 3:189,360,171...189,366,697
|
|
| G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [cilostazol results in increased activity of PPARG protein]; zinc protoporphyrin inhibits the reaction [rosiglitazone results in increased activity of PPARG protein]
|
CTD |
PMID:21660147 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
| G
|
Ppil1
|
peptidylprolyl isomerase like 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of PPIL1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr20:7,303,919...7,323,962
Ensembl chr20:7,303,922...7,318,781
|
|
| G
|
Prdx2
|
peroxiredoxin 2
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of PRDX2 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr19:40,085,788...40,091,083
Ensembl chr19:40,084,430...40,091,006
|
|
| G
|
Prr11
|
proline rich 11
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of PRR11 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr10:72,396,127...72,440,643
Ensembl chr10:72,398,667...72,418,275
|
|
| G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [tricarbonyldichlororuthenium (II) dimer inhibits the reaction [F2 protein results in increased expression of PTGS2 protein]]; zinc protoporphyrin promotes the reaction [Arsenic Trioxide results in increased expression of PTGS2] zinc protoporphyrin affects the reaction [BACH1 protein affects the reaction [Doxorubicin results in increased expression of PTGS2 mRNA]]; zinc protoporphyrin affects the reaction [BACH1 protein affects the reaction [Doxorubicin results in increased expression of PTGS2 protein]]; zinc protoporphyrin inhibits the reaction [Cadmium results in increased expression of PTGS2 protein] zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]; zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
|
CTD |
PMID:23649692 PMID:24003391 PMID:26385185 PMID:30261164 PMID:38573338 PMID:39025289 More...
|
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
| G
|
Ptpn12
|
protein tyrosine phosphatase, non-receptor type 12
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of PTPN12 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 4:14,913,071...14,985,084
Ensembl chr 4:14,913,218...14,985,284
|
|
| G
|
Ptpro
|
protein tyrosine phosphatase, receptor type, O
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of PTPRO mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 4:171,895,104...172,105,911
Ensembl chr 4:171,895,232...172,105,903
|
|
| G
|
Rap2c
|
RAP2C, member of RAS oncogene family
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of RAP2C mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr X:135,388,881...135,401,998
Ensembl chr X:135,388,882...135,401,998
|
|
| G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]]; zinc protoporphyrin inhibits the reaction [Curcumin inhibits the reaction [quinocetone results in increased expression of RELA mRNA]]; zinc protoporphyrin promotes the reaction [quinocetone results in increased expression of RELA mRNA] zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in decreased expression of RELA protein] zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased localization of and results in increased activity of RELA protein]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein modified form]]
|
CTD |
PMID:19608869 PMID:20131233 PMID:20357190 PMID:21925249 PMID:27375190 PMID:27523796 More...
|
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
| G
|
Rgcc
|
regulator of cell cycle
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of RGCC mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr15:61,071,574...61,084,408
Ensembl chr15:61,071,574...61,084,408
|
|
| G
|
Scaf11
|
SR-related CTD-associated factor 11
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of SCAF11 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 7:129,450,872...129,503,280
Ensembl chr 7:129,417,955...129,503,280
|
|
| G
|
Scamp1
|
secretory carrier membrane protein 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of SCAMP1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 2:27,168,863...27,251,637
Ensembl chr 2:27,168,864...27,251,742
|
|
| G
|
Sec23b
|
Sec23 homolog B, COPII coat complex component
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of SEC23B mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 3:152,392,340...152,434,813
Ensembl chr 3:152,392,308...152,434,800
|
|
| G
|
Sel1l
|
SEL1L adaptor subunit of SYVN1 ubiquitin ligase
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of SEL1L mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 6:116,466,163...116,510,436
Ensembl chr 6:116,466,163...116,510,578
|
|
| G
|
Sirt1
|
sirtuin 1
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Fenofibrate results in increased expression of SIRT1 protein]
|
CTD |
PMID:34520103 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000
|
|
| G
|
Slc22a3
|
solute carrier family 22 member 3
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of SLC22A3 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 1:50,783,218...50,872,358
Ensembl chr 1:50,783,218...50,872,353
|
|
| G
|
Slc35e1
|
solute carrier family 35, member E1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of SLC35E1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr16:17,384,980...17,398,227
Ensembl chr16:17,385,030...17,397,310
|
|
| G
|
Smcr8
|
SMCR8-C9orf72 complex subunit
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of SMCR8 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr10:45,957,146...45,968,388
Ensembl chr10:45,957,104...45,968,389
|
|
| G
|
Sod2
|
superoxide dismutase 2
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of SOD2 mRNA; zinc protoporphyrin inhibits the reaction [HIF1A protein results in increased activity of SOD2 protein]
|
CTD |
PMID:17066447 PMID:22839698 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168
|
|
| G
|
Sptbn1
|
spectrin, beta, non-erythrocytic 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of SPTBN1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr14:108,042,629...108,217,884
Ensembl chr14:108,042,629...108,217,836
|
|
| G
|
Src
|
SRC proto-oncogene, non-receptor tyrosine kinase
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [SRC protein binds to NCF1 protein]]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [SRC protein binds to TNFRSF1A protein]]]
|
CTD |
PMID:19608869 |
|
NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:166,511,985...166,559,462
|
|
| G
|
Ssbp3
|
single stranded DNA binding protein 3
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of SSBP3 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 5:126,920,145...127,057,968
Ensembl chr 5:126,919,120...127,056,799
|
|
| G
|
St3gal1
|
ST3 beta-galactoside alpha-2,3-sialyltransferase 1
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of ST3GAL1 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 7:100,734,300...100,802,443
Ensembl chr 7:100,734,300...100,745,242
|
|
| G
|
Stat1
|
signal transducer and activator of transcription 1
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [Ozone results in increased phosphorylation of STAT1 protein]
|
CTD |
PMID:19061877 |
|
NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:56,911,523...57,077,346
|
|
| G
|
Stat3
|
signal transducer and activator of transcription 3
|
multiple interactions
|
EXP ISO
|
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Glucose results in decreased phosphorylation of STAT3 protein]]; zinc protoporphyrin inhibits the reaction [Propofol inhibits the reaction [Glucose results in decreased phosphorylation of STAT3 protein]] zinc protoporphyrin inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]
|
CTD |
PMID:24095726 PMID:24810525 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359
|
|
| G
|
Tgfb1
|
transforming growth factor, beta 1
|
affects expression decreases secretion increases expression
|
EXP
|
zinc protoporphyrin affects the expression of TGFB1 zinc protoporphyrin results in decreased secretion of TGFB1 protein zinc protoporphyrin results in increased expression of TGFB1 protein
|
CTD |
PMID:21163135 PMID:23525258 PMID:23704825 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
| G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
affects expression multiple interactions
|
EXP ISO
|
zinc protoporphyrin affects the expression of TIMP1 zinc protoporphyrin promotes the reaction [ALB protein results in increased expression of TIMP1 protein]
|
CTD |
PMID:21163135 PMID:23704825 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
| G
|
Tlr2
|
toll-like receptor 2
|
multiple interactions
|
EXP
|
zinc protoporphyrin promotes the reaction [TLR2 protein binds to MYD88 protein]
|
CTD |
PMID:25780291 |
|
NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:171,497,060...171,520,194
|
|
| G
|
Tlr4
|
toll-like receptor 4
|
multiple interactions
|
EXP
|
zinc protoporphyrin promotes the reaction [TLR4 protein binds to MYD88 protein]
|
CTD |
PMID:25780291 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
| G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [cilostazol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; zinc protoporphyrin inhibits the reaction [cilostazol results in decreased susceptibility to TNF protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [SRC protein binds to NCF1 protein]]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [SRC protein binds to TNFRSF1A protein]]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased abundance of Reactive Oxygen Species]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of IL6 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]] [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of TNF mRNA; [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with zinc protoporphyrin] results in increased expression of TNF protein; zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; zinc protoporphyrin inhibits the reaction [naringenin results in decreased activity of TNF protein]; zinc protoporphyrin inhibits the reaction [perflexane inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein]]; zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in increased expression of TNF protein]]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of TNF mRNA]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of TNF protein] zinc protoporphyrin inhibits the reaction [8-oxoberberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]]; zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; zinc protoporphyrin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased localization of and results in increased activity of RELA protein]]; zinc protoporphyrin inhibits the reaction [manganese chloride promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein]]; zinc protoporphyrin inhibits the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]
|
CTD |
PMID:19608869 PMID:20052772 PMID:20131233 PMID:20360627 PMID:21660147 PMID:21925249 PMID:21963524 PMID:22709785 PMID:24095726 PMID:26747958 PMID:30261164 PMID:32621855 PMID:33049506 PMID:35691465 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
| G
|
Tnfrsf1a
|
TNF receptor superfamily member 1A
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [SRC protein binds to TNFRSF1A protein]]]
|
CTD |
PMID:19608869 |
|
NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:159,837,032...159,849,816
|
|
| G
|
Tnrc6a
|
trinucleotide repeat containing adaptor 6A
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of TNRC6A mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 1:186,992,457...187,146,764
Ensembl chr 1:186,992,504...187,146,756
|
|
| G
|
Tollip
|
toll interacting protein
|
decreases expression
|
EXP
|
zinc protoporphyrin results in decreased expression of TOLLIP protein
|
CTD |
PMID:25780291 |
|
NCBI chr 1:206,391,120...206,413,809
Ensembl chr 1:206,380,308...206,411,988
|
|
| G
|
Tp53
|
tumor protein p53
|
multiple interactions
|
ISO EXP
|
[zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [cobaltiprotoporphyrin results in increased expression of TP53 protein] zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in decreased expression of TP53 protein] zinc protoporphyrin inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in increased expression of TRP53 protein]]
|
CTD |
PMID:18042465 PMID:20357190 PMID:22763982 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
| G
|
Traf6
|
TNF receptor associated factor 6
|
multiple interactions
|
EXP
|
zinc protoporphyrin promotes the reaction [TRAF6 protein binds to MYD88 protein]
|
CTD |
PMID:25780291 |
|
NCBI chr 3:108,418,537...108,443,330
Ensembl chr 3:108,418,513...108,443,328
|
|
| G
|
Ubxn2a
|
UBX domain protein 2A
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of UBXN2A mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 6:33,603,804...33,645,958
Ensembl chr 6:33,603,804...33,632,202 Ensembl chr20:33,603,804...33,632,202
|
|
| G
|
Usp13
|
ubiquitin specific peptidase 13
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of USP13 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 2:117,502,811...117,617,049
Ensembl chr 2:117,505,122...117,630,161
|
|
| G
|
Usp34
|
ubiquitin specific peptidase 34
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of USP34 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr14:101,487,110...101,677,519
Ensembl chr14:101,487,153...101,678,632
|
|
| G
|
Vcam1
|
vascular cell adhesion molecule 1
|
multiple interactions
|
ISO EXP
|
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]]; zinc protoporphyrin inhibits the reaction [HMOX1 protein inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]] zinc protoporphyrin promotes the reaction [Indomethacin results in increased expression of VCAM1 mRNA]
|
CTD |
PMID:19608869 PMID:23892052 |
|
NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801
|
|
| G
|
Vdr
|
vitamin D receptor
|
affects abundance
|
ISO
|
VDR gene polymorphism affects the abundance of zinc protoporphyrin
|
CTD |
PMID:25963508 |
|
NCBI chr 7:130,864,764...130,916,757
Ensembl chr 7:130,866,745...130,916,757
|
|
| G
|
Vps33a
|
VPS33A core subunit of CORVET and HOPS complexes
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of VPS33A mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr12:38,685,484...38,710,668
Ensembl chr12:38,685,538...38,712,277
|
|
| G
|
Wsb2
|
WD repeat and SOCS box-containing 2
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of WSB2 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr12:44,878,483...44,899,474
Ensembl chr12:44,878,509...44,899,474
|
|
| G
|
Zfp36
|
zinc finger protein 36
|
multiple interactions
|
ISO
|
zinc protoporphyrin inhibits the reaction [[Nicotine co-treated with Lipopolysaccharides] results in increased expression of ZFP36 mRNA]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of ZFP36 mRNA]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of ZFP36 mRNA]; zinc protoporphyrin inhibits the reaction [Nicotine results in increased expression of ZFP36 mRNA]
|
CTD |
PMID:24095726 |
|
NCBI chr 1:92,796,628...92,799,108
Ensembl chr 1:92,796,628...92,799,108
|
|
| G
|
Zfp827
|
zinc finger protein 827
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of ZNF827 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr19:45,624,849...45,791,739
Ensembl chr19:45,614,604...45,844,430
|
|
| G
|
Zfyve16
|
zinc finger FYVE-type containing 16
|
multiple interactions
|
ISO
|
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of ZFYVE16 mRNA
|
CTD |
PMID:22839698 |
|
NCBI chr 2:25,448,264...25,495,180
Ensembl chr 2:25,448,829...25,483,295
|
|
|
|
| G
|
Anxa5
|
annexin A5
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of ANXA5 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 2:121,242,133...121,272,935
Ensembl chr 2:121,242,136...121,281,400
|
|
| G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of BAX mRNA; pyrithione zinc results in increased expression of BAX protein
|
CTD |
PMID:20151177 PMID:21424779 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
| G
|
Bbc3
|
Bcl-2 binding component 3
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of BBC3 protein
|
CTD |
PMID:20151177 |
|
NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:86,141,603...86,150,666
|
|
| G
|
Bcl2l1
|
Bcl2-like 1
|
decreases expression
|
ISO
|
pyrithione zinc results in decreased expression of BCL2L1 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907 Ensembl chr 1:161,745,540...161,764,907
|
|
| G
|
Bid
|
BH3 interacting domain death agonist
|
increases cleavage
|
ISO
|
pyrithione zinc results in increased cleavage of BID protein
|
CTD |
PMID:20151177 |
|
NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:155,785,377...155,808,275
|
|
| G
|
Casp1
|
caspase 1
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of CASP1 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275
|
|
| G
|
Casp3
|
caspase 3
|
increases activity
|
ISO
|
pyrithione zinc results in increased activity of CASP3 protein
|
CTD |
PMID:20151177 PMID:21557991 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
| G
|
Casp7
|
caspase 7
|
increases activity
|
ISO
|
pyrithione zinc results in increased activity of CASP7 protein
|
CTD |
PMID:20151177 |
|
NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512
|
|
| G
|
Casp8
|
caspase 8
|
increases activity increases expression
|
ISO
|
pyrithione zinc results in increased activity of CASP8 protein pyrithione zinc results in increased expression of CASP8 mRNA
|
CTD |
PMID:20151177 PMID:21424779 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
| G
|
Casp9
|
caspase 9
|
increases activity
|
ISO
|
pyrithione zinc results in increased activity of CASP9 protein
|
CTD |
PMID:20151177 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
| G
|
Ccng1
|
cyclin G1
|
decreases expression
|
ISO
|
pyrithione zinc results in decreased expression of CCNG1 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr10:25,678,503...25,684,876
Ensembl chr10:25,677,885...25,683,766
|
|
| G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of CDKN1A mRNA; pyrithione zinc results in increased expression of CDKN1A protein
|
CTD |
PMID:21424779 PMID:21557991 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
| G
|
Cdkn2a
|
cyclin-dependent kinase inhibitor 2A
|
affects expression
|
ISO
|
pyrithione zinc affects the expression of CDKN2A protein
|
CTD |
PMID:21557991 |
|
NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:109,100,772...109,119,248
|
|
| G
|
Chek2
|
checkpoint kinase 2
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of CHEK2 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr12:51,448,838...51,481,159
Ensembl chr12:51,449,140...51,480,667
|
|
| G
|
Cryab
|
crystallin, alpha B
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of CRYAB mRNA; pyrithione zinc results in increased expression of CRYAB protein
|
CTD |
PMID:19809895 |
|
NCBI chr 8:59,989,885...59,995,532
Ensembl chr 8:59,989,814...59,995,528
|
|
| G
|
Ctsd
|
cathepsin D
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of CTSD protein
|
CTD |
PMID:20151177 |
|
NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:206,956,944...206,968,821
|
|
| G
|
Cycs
|
cytochrome c, somatic
|
affects localization
|
ISO
|
pyrithione zinc affects the localization of CYCS protein
|
CTD |
PMID:21557991 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816 Ensembl chr18:80,982,668...80,984,816
|
|
| G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of CYP1A1 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
| G
|
Cyp7a1
|
cytochrome P450 family 7 subfamily A member 1
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of CYP7A1 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202
|
|
| G
|
Ddb1
|
damage-specific DNA binding protein 1
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of DDB1 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 1:216,677,810...216,703,605
Ensembl chr 1:216,677,810...216,703,596
|
|
| G
|
Ddit3
|
DNA-damage inducible transcript 3
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of DDIT3 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
|
|
| G
|
Dnaja1
|
DnaJ heat shock protein family (Hsp40) member A1
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of DNAJA1 mRNA; pyrithione zinc results in increased expression of DNAJA1 protein
|
CTD |
PMID:19809895 PMID:21424779 |
|
NCBI chr 5:60,638,404...60,649,315
Ensembl chr 5:60,638,410...60,650,160
|
|
| G
|
Dnajb4
|
DnaJ heat shock protein family (Hsp40) member B4
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of DNAJB4 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 2:243,790,296...243,819,042
Ensembl chr 2:243,790,297...243,819,042
|
|
| G
|
Egr1
|
early growth response 1
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of EGR1 mRNA
|
CTD |
PMID:19809895 |
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843
|
|
| G
|
Ephx2
|
epoxide hydrolase 2
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of EPHX2 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr15:44,465,447...44,503,157
Ensembl chr15:44,465,448...44,503,160
|
|
| G
|
Fmo1
|
flavin containing dimethylaniline monoxygenase 1
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of FMO1 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr13:77,715,405...77,747,666
Ensembl chr13:77,715,402...77,747,874
|
|
| G
|
Fmo5
|
flavin containing dimethylaniline monoxygenase 5
|
decreases expression increases expression
|
ISO
|
pyrithione zinc results in decreased expression of FMO5 mRNA pyrithione zinc results in increased expression of FMO5 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 2:187,885,741...187,938,468
Ensembl chr 2:187,910,964...187,938,464
|
|
| G
|
Gadd45a
|
growth arrest and DNA-damage-inducible, alpha
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of GADD45A mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807
|
|
| G
|
Gdf15
|
growth differentiation factor 15
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of GDF15 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022
|
|
| G
|
Gpx1
|
glutathione peroxidase 1
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of GPX1 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581
|
|
| G
|
Gsr
|
glutathione-disulfide reductase
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of GSR mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394
|
|
| G
|
Gstm5
|
glutathione S-transferase, mu 5
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of GSTM3 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 2:198,219,769...198,222,732
Ensembl chr 2:198,219,647...198,222,731
|
|
| G
|
Hmox1
|
heme oxygenase 1
|
increases expression multiple interactions
|
ISO
|
pyrithione zinc results in increased expression of HMOX1 mRNA; pyrithione zinc results in increased expression of HMOX1 protein MTF1 gene mutant form promotes the reaction [pyrithione zinc results in increased expression of HMOX1 mRNA]
|
CTD |
PMID:19809895 PMID:21424779 PMID:23085594 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
| G
|
Hsf1
|
heat shock transcription factor 1
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of HSF1 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665
|
|
| G
|
Hsp90aa1
|
heat shock protein 90 alpha family class A member 1
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of HSP90AA1 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499
|
|
| G
|
Hsp90ab1
|
heat shock protein 90 alpha family class B member 1
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of HSP90AB1 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 9:22,930,249...22,935,929
Ensembl chr 9:22,931,070...22,935,926
|
|
| G
|
Hspa1a
|
heat shock protein family A (Hsp70) member 1A
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of HSPA1A mRNA; pyrithione zinc results in increased expression of HSPA1A protein
|
CTD |
PMID:19809895 PMID:21424779 |
|
NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,855,780...3,877,979
|
|
| G
|
Hspa1l
|
heat shock protein family A (Hsp70) member 1 like
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of HSPA1L mRNA; pyrithione zinc results in increased expression of HSPA1L protein
|
CTD |
PMID:19809895 PMID:21424779 |
|
NCBI chr20:3,853,496...3,860,223
Ensembl chr20:3,853,331...3,876,877
|
|
| G
|
Hspa4
|
heat shock protein family A (Hsp70) member 4
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of HSPA4 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr10:37,908,866...37,951,994
Ensembl chr10:37,908,866...37,949,835
|
|
| G
|
Hspa5
|
heat shock protein family A (Hsp70) member 5
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of HSPA5 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790
|
|
| G
|
Hspa6l-ps1
|
heat shock protein family A (Hsp70) member 6 like, pseudogene 1
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of HSPA6 mRNA; pyrithione zinc results in increased expression of HSPA6 protein
|
CTD |
PMID:19809895 PMID:21424779 |
|
NCBI chr13:85,805,911...85,807,052
|
|
| G
|
Hspa8
|
heat shock protein family A (Hsp70) member 8
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of HSPA8 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:50,080,199...50,084,372
|
|
| G
|
Hspd1
|
heat shock protein family D (Hsp60) member 1
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of HSPD1 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 9:64,073,610...64,084,332
Ensembl chr 9:64,073,611...64,084,037
|
|
| G
|
Hspe1
|
heat shock protein family E (Hsp10) member 1
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of HSPE1 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 9:64,084,327...64,087,415
Ensembl chr 9:64,085,068...64,087,502
|
|
| G
|
Hsph1
|
heat shock protein family H (Hsp110) member 1
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of HSPH1 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr12:10,427,368...10,446,602
Ensembl chr12:10,427,297...10,446,891
|
|
| G
|
Igfbp6
|
insulin-like growth factor binding protein 6
|
decreases expression
|
ISO
|
pyrithione zinc results in decreased expression of IGFBP6 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 7:135,154,919...135,159,550
Ensembl chr 7:135,154,685...135,159,795
|
|
| G
|
Kcnh2
|
potassium voltage-gated channel subfamily H member 2
|
decreases activity
|
ISO
|
pyrithione zinc results in decreased activity of KCNH2 protein
|
CTD |
PMID:28551711 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421
|
|
| G
|
Lta
|
lymphotoxin alpha
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of LTA mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr20:3,622,291...3,625,852
Ensembl chr20:3,623,527...3,625,533
|
|
| G
|
Mdm2
|
MDM2 proto-oncogene
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of MDM2 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791
|
|
| G
|
Mt1a
|
metallothionein 1A
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of MT1 mRNA
|
CTD |
PMID:23085594 |
|
NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200 Ensembl chr X:79,695,809...79,696,200 Ensembl chr19:79,695,809...79,696,200
|
|
| G
|
Mt2
|
metallothionein 2
|
increases expression multiple interactions
|
ISO
|
pyrithione zinc results in increased expression of MT2A mRNA; pyrithione zinc results in increased expression of MT2A protein [zinc chloride co-treated with pyrithione zinc] results in increased expression of MT2A mRNA
|
CTD |
PMID:20151177 PMID:20801194 PMID:21424779 |
|
NCBI chr19:10,837,934...10,838,708
Ensembl chr19:10,837,927...10,838,709
|
|
| G
|
Mtf1
|
metal-regulatory transcription factor 1
|
multiple interactions
|
ISO
|
MTF1 gene mutant form promotes the reaction [pyrithione zinc results in increased expression of HMOX1 mRNA]
|
CTD |
PMID:23085594 |
|
NCBI chr 5:142,347,024...142,391,810
Ensembl chr 5:142,347,054...142,391,810
|
|
| G
|
Mtor
|
mechanistic target of rapamycin kinase
|
decreases expression
|
ISO
|
pyrithione zinc results in decreased expression of MTOR protein
|
CTD |
PMID:21557991 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435
|
|
| G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
increases expression multiple interactions
|
ISO
|
pyrithione zinc results in increased expression of NFE2L2 protein SQSTM1 protein affects the reaction [pyrithione zinc results in increased expression of NFE2L2 protein]
|
CTD |
PMID:30261176 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
| G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of NFKB1 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
|
|
| G
|
Nfkbia
|
NFKB inhibitor alpha
|
decreases expression
|
ISO
|
pyrithione zinc results in decreased expression of NFKBIA mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
| G
|
Nos2
|
nitric oxide synthase 2
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of NOS2A mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
| G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions affects response to substance increases activity
|
ISO
|
Pentetic Acid inhibits the reaction [pyrithione zinc results in increased activity of PARP1 protein] PARP1 protein affects the reaction [pyrithione zinc results in decreased abundance of Adenosine Triphosphate] PARP1 protein affects the susceptibility to pyrithione zinc
|
CTD |
PMID:19809895 PMID:21424779 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
| G
|
Por
|
cytochrome p450 oxidoreductase
|
decreases expression
|
ISO
|
pyrithione zinc results in decreased expression of POR mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809
|
|
| G
|
Prdx1
|
peroxiredoxin 1
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of PRDX1 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 5:135,383,906...135,399,504
Ensembl chr 5:135,383,906...135,399,504
|
|
| G
|
Ptgs1
|
prostaglandin-endoperoxide synthase 1
|
decreases expression
|
ISO
|
pyrithione zinc results in decreased expression of PTGS1 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990
|
|
| G
|
Rad23a
|
RAD23 homolog A, nucleotide excision repair protein
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of RAD23A mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr19:40,219,235...40,225,543
Ensembl chr19:40,219,636...40,225,543
|
|
| G
|
Rad50
|
RAD50 double strand break repair protein
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of RAD50 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr10:38,310,147...38,362,100
Ensembl chr10:38,310,147...38,362,100
|
|
| G
|
Rps6
|
ribosomal protein S6
|
affects phosphorylation
|
ISO
|
pyrithione zinc affects the phosphorylation of RPS6 protein
|
CTD |
PMID:21557991 |
|
NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:106,417,680...106,420,566
|
|
| G
|
Serpine1
|
serpin family E member 1
|
decreases expression
|
ISO
|
pyrithione zinc results in decreased expression of SERPINE1 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357
|
|
| G
|
Sod1
|
superoxide dismutase 1
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of SOD1 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
| G
|
Sod2
|
superoxide dismutase 2
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of SOD2 mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168
|
|
| G
|
Sqstm1
|
sequestosome 1
|
multiple interactions
|
ISO
|
SQSTM1 protein affects the reaction [pyrithione zinc results in increased expression of NFE2L2 protein]
|
CTD |
PMID:30261176 |
|
NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750
|
|
| G
|
Tgfb1
|
transforming growth factor, beta 1
|
decreases activity
|
ISO
|
pyrithione zinc results in decreased activity of TGFB1 protein
|
CTD |
PMID:31652400 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
| G
|
Tnf
|
tumor necrosis factor
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of TNF mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
| G
|
Tp53
|
tumor protein p53
|
multiple interactions increases expression
|
ISO
|
Pentetic Acid inhibits the reaction [pyrithione zinc results in increased expression of TP53 protein]; Pentetic Acid inhibits the reaction [pyrithione zinc results in increased phosphorylation of TP53 protein]; pyrithione zinc results in increased expression of and results in increased phosphorylation of TP53 protein; pyrithione zinc results in increased phosphorylation of and results in increased activity of TP53 protein pyrithione zinc results in increased expression of TP53 mRNA; pyrithione zinc results in increased expression of TP53 protein
|
CTD |
PMID:20151177 PMID:21424779 PMID:21557991 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
| G
|
Ung
|
uracil-DNA glycosylase
|
increases expression
|
ISO
|
pyrithione zinc results in increased expression of UNG mRNA
|
CTD |
PMID:21424779 |
|
NCBI chr12:48,145,838...48,154,789
Ensembl chr12:48,145,838...48,155,257
|
|
|
|
| G
|
Ache
|
acetylcholinesterase
|
decreases expression
|
EXP
|
Zineb results in decreased expression of ACHE protein
|
CTD |
PMID:3868355 |
|
NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410
|
|
| G
|
Alpl
|
alkaline phosphatase, biomineralization associated
|
multiple interactions
|
ISO
|
Zineb inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA]
|
CTD |
PMID:29149346 |
|
NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167
|
|
| G
|
Casp3
|
caspase 3
|
increases activity
|
ISO
|
Zineb results in increased activity of CASP3 protein
|
CTD |
PMID:17189834 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
| G
|
Hsd11b2
|
hydroxysteroid 11-beta dehydrogenase 2
|
decreases activity
|
ISO
|
Zineb results in decreased activity of HSD11B2 protein
|
CTD |
PMID:22796344 |
|
NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812
|
|
| G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
multiple interactions increases activity
|
ISO
|
[Endosulfan co-treated with Zineb] results in increased activity of NFKB1 protein Zineb results in increased activity of NFKB1 protein
|
CTD |
PMID:17189834 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
|
|
| G
|
Nr3c2
|
nuclear receptor subfamily 3, group C, member 2
|
multiple interactions
|
ISO
|
Zineb inhibits the reaction [Aldosterone affects the localization of NR3C2 protein]; Zineb inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]
|
CTD |
PMID:29149346 |
|
NCBI chr19:47,619,853...47,964,089
Ensembl chr19:47,619,853...47,964,078
|
|
| G
|
Park7
|
Parkinsonism associated deglycase
|
decreases activity
|
ISO
|
Zineb results in decreased activity of PARK7 protein
|
CTD |
PMID:36842454 |
|
NCBI chr 5:166,636,551...166,659,825
Ensembl chr 5:166,636,552...166,659,825
|
|
| G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
ISO
|
Zineb inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Zineb promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]
|
CTD |
PMID:15256756 PMID:16112155 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
| G
|
Tpo
|
thyroid peroxidase
|
decreases activity
|
ISO
|
Zineb results in decreased activity of TPO protein
|
CTD |
PMID:9248629 |
|
NCBI chr 6:52,425,998...52,495,793
Ensembl chr 6:52,426,010...52,495,793
|
|